REGENXBIO, which is developing gene therapies for rare diseases and licensing out gene delivery technology, announced terms for its IPO on Tuesday.
The Rockville, MD-based company plans to raise $100 million by offering 5.6 million shares at a price range of $17 to $19. At the midpoint of the proposed range, REGENXBIO would command a fully diluted market value of $492 million.
REGENXBIO, which was founded in 2008 and booked $4 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol RGNX. REGENXBIO initially filed confidentially on 7/1/2015. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray are the joint bookrunners on the deal.
